Cyclophosphamide,Fludarabine

Phase 1Cell therapy

HHebei Senlang Biotechnology Inc., Ltd.

Cyclophosphamide,Fludarabine is one of 133 small molecule programs targeting Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

132

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Metastatic Non Small Cell Lung CancerRecruiting

Relapsed/refractoryUnknown status

Clinical TrialUnknown status

LymphomaPreclinical

Active, not recruiting

Metastatic Non Small Cell Lung CancerPhase 1

Recruiting

Relapsed/refractoryPreclinical

Unknown status

Clinical TrialPreclinical

Unknown status

Competition

Competitive Landscape

375 competitors in Lymphoma

#DrugCompanyPhaseTrials

Zofran

Novartis

Preclinical

2 2

Norvir

AbbVie

Preclinical

1 3

Cabenuva

GSK

Preclinical

1 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Cyclophosphamide,Fludarabine

HHebei Senlang Biotechnology Inc., Ltd.

Phase 1

2 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2040

Phase 1Recruiting

Metastatic Non Small Cell Lung Cancer

NCT07116057

Clinical

Trials by Indication[1]

Lymphoma2 trials

A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·N/A·NCT04666168·200 enrolled

A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·N/A·NCT04665063·20 enrolled

B-cell acute lymphoblastic leukemia1 trial

Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·Phase 1·NCT05225831·100 enrolled

Clinical Trial1 trial

Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·N/A·NCT04610125·30 enrolled

Relapsed/Refractory1 trial

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·N/A·NCT04665076·60 enrolled

Metastatic Non Small Cell Lung Cancer1 trial

Phase I Clinical Trial of Autologous Folate Receptor-Alpha Redirected T Cells in Patients With FRa+ Cancers

Recruiting·UUniversity of Pennsylvania·Phase 1·NCT07116057·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Cyclophosphamide,Fludarabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cyclophosphamide,Fludarabine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cyclophosphamide,Fludarabine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hebei Senlang Biotechnology Inc., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: HHebei Senlang Biotechnology Inc., Ltd.

Cyclophosphamide,Fludarabine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2040

Trials by Indication[1]

Lymphoma2 trials

B-cell acute lymphoblastic leukemia1 trial

Clinical Trial1 trial

Relapsed/Refractory1 trial

Metastatic Non Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News